Editor Spotlight

^{Section: Combination Strategies}

Dr Alessio Cortellini is a consultant in medical oncology and a clinical scientist with a special interest in immunotherapy of cancer and lung cancer. After leading the immunotherapy program at University of L’Aquila in Italy for more than a year, he moved to London in 2020, where he worked in the early phase clinical trial unit at Imperial College London.

In July 2022, he moved to Rome and he is now working at the Fondazione Policlinico Universitario Campus Bio-Medico in Rome. However, given the fruitful collaboration and the number of high-level research goals achieved during his fellowship at Imperial College, he is keeping his honorary academic post as Honorary Clinical Lecturer with Imperial College London.

^{Section: Immunobiology and Immunotherapy}

Sarah Warren, PhD is the Senior Director of Research Technologies and Business Development Planning at Kite Pharma. She focuses on advancing cell therapies through integration of novel approaches to CAR-T design and development into Kite's pipeline. Prior to joining Kite, she led Translational Science at NanoString where she focused on collaborating with investigators to use novel spatial and bulk profiling technologies to address unanswered questions in immune oncology. She is a director-at-large for SITC and is an Associate Editor for the Journal of Translational Medicine. She holds a PhD in Immunology from the University of Washington where she studies host-pathogen interactions.